Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease
18 janv. 2024 03h00 HE
|
Orphalan
Orphalan announces China NMPA’s approval of its trientine tetrahydrochloride product for the treatment of Wilson disease Paris, France 18 January, 2024 - Orphalan SA (“Orphalan” or “the Company”),...
Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
20 avr. 2023 07h00 HE
|
Orphalan
Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine — Oral administration offers dosing flexibility and...
Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology
30 sept. 2022 07h00 HE
|
Orphalan
Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology Trial supported Orphalan’s successful application to the United States Food and Drug...
Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology
30 sept. 2022 02h00 HE
|
Orphalan
Orphalan announces publication of results from the CHELATE trial in The Lancet Gastroenterology & Hepatology Trial supported Orphalan’s successful application to the United States Food and Drug...
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”)
26 juil. 2022 07h00 HE
|
Orphalan
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”) World’s first global Wilson’s Registry will provide an international...
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”)
26 juil. 2022 02h00 HE
|
Orphalan
Orphalan announces enrolment of the first five patients in the International Wilson's Disease Patient Registry (“iWD Registry”) World’s first global Wilson’s Registry will provide an international...
Orphalan announces data from secondary analyses of the CHELATE trial for maintenance patients with Wilson’s Disease
22 juin 2022 03h00 HE
|
Orphalan
Orphalan announces data from secondary analyses of the CHELATE trial for maintenance patients with Wilson’s Disease — Data from the company’s CHELATE trial to be presented today during an oral...
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine
02 mai 2022 07h00 HE
|
Orphalan
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine Paris, France 2 May 2022 – Orphalan SA...
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine
02 mai 2022 02h00 HE
|
Orphalan
Orphalan announces FDA approval of Cuvrior™ for the treatment of adult patients with stable Wilson’s disease who are de-coppered and tolerant to penicillamine Paris, France 2 May 2022 – Orphalan SA...
Orphalan strengthens its management team with two key appointments
01 févr. 2022 02h00 HE
|
Orphalan
Orphalan strengthens its management team with two key appointments Paris, France 1 February 2022 – Orphalan SA, a Company that identifies, develops, and delivers therapies worldwide for orphan...